KNOWLEDGE BANK

Interviews

Innovation Management at Bachem

Chief Technology Officer, Bachem Holding AG
Gnther Loidl joined Bachem in He held several functions in Research and Development RD and Active Pharmaceutical Ingredient Manufacturing and became Vice President RD in Since he is CTO of the Bachem Group and a member of the Corporate Executive Committee He studied chemistry in Regensburg Germany and Leeds UK and obtained his doctorate under the supervision of Luis Moroder at the Max Planck In...

Articles

Evolution of eCTD from version 1 to 4

The electronic Common Technical Document eCTD has undergone significant evolution from its inception to the current version The eCTD standard is primarily used for the submission of regulatory information to health authorities providing a structured electronic format for regulatory submissions

Research Insights

Clinically Adjudicated Deceased Donor Acute Kidney Injury and Graft Outcomes

Acute kidney injury AKI in deceased donors is not associated with graft failure GF We hypothesize that hemodynamic AKI hAKI comprises the majority of donor AKI and may explain this lack of association Less than of patients on the waiting list receive kidney transplants each year and approximately thirteen

Case Studies

Effects Of Low-dose Ibuprofen Supplementation And Resistance Training On Bone And Muscle In Postmenopausal Women: A Randomized & Controlled Trial

Abstract Purpose To compare the effects of nine months of exercise training and ibuprofen supplementation given immediately after exercise sessions on bone and muscle in postmenopausal women Methods In a doubleblin

Techno Trends

Novel Therapy, Toripalimab, Developed to Treat Nasopharyngeal Carcinoma

Toripalimab a novel therapy has been discovered for the treatment of nasopharyngeal carcinoma by Junshi Biosciences Toripalimab the first antiPD monoclonal antibody developed for the treatment of Nasopharyngeal carcinoma

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Natural Polymers and Fibers in Drug Delivery

Dr. Meghraj V. Suryawanshi

Dr. Meghraj V. Suryawanshi is an Associate Professor and Co-Founder of Sandip Institute of Pharmaceutical Sciences. He holds M.Pharm, MBA, PDCR, and Ph.D. degrees. With over 7 years of research experience and 4 years in teaching, his expertise lies in polymer science, novel drug delivery systems (NDDS), and intellectual property rights (IPR). Dr. Suryawanshi has authored more than 55 publications, 8 books, and holds several patents. He actively leads innovative pharmaceutical research with a strong focus on translational impact.

Akshata Yashwant Patne

Akshata Yashwant Patne is a pharmaceutical nanotechnology expert with over 3 years of experience in clinical research, drug delivery, and AI-driven therapeutics. She has led nanoparticle-based studies, published peer-reviewed articles, and actively mentors students, combining science, innovation, and leadership across academia, research, and global scientific communities.

2

A BITTER PILL: Exploring the Realm of Drug Counterfeiting

Stephen Ward

Stephen Ward is Pinkerton’s the Vice President of East Coast USA. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.

Angelo Krizmanic

Angelo Krizmanic is Pinkerton’s Vice President of Asia Pacific. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.

3

Meet scientist Daria Donati

Daria Donati

Daria’s work is ongoing. Her role at Cytiva involves identifying new and innovative technologies that can help in the development of therapeutics. This means building partnerships, improving manufacturing processes and, ultimately, getting life- saving drugs to the people who need them most.

 

4

Pharma Firms Must Come Together, Ensure Access to Antibiotics in Poor Countries to Take on Superbugs

Saransh Chaudhary

Entrusted with the mandate of augmenting and monetising the company’s intellectual property wealth and driving key tactical initiatives, Saransh Chaudhary joined Venus Remedies in 2016 as Strategic Board Advisor after completing his undergraduate degree in Accounting & Finance from Cass Business School, London. Two years later, he assumed charge as President of the company’s Global Critical Care division and CEO of Venus Medicine Research Centre (VMRC), its R&D wing. In these roles, he translates priorities into actionable strategies.

5

Lipid Based Drug Delivery Systems

Venu Madhav Katla

Venu Madhav Katla working as Professor in Department of Pharmaceutics and having over 15 years of teaching and research experience. He had more than 15 research and review publications. He is having 10 national as well as international presentations in his credit. He guided around 25 M.Pharm and one Ph.D student (Pursuing).

 

Sridhar Babu Gummadi

Sridhar Babu Gummadi working as Professor and having over 18 years of teaching and research experience. He is having more than 20 research and review publications. Had 10 national as well as international presentations in his credit. He had one patent and one book as publication. He guided around 35 M.Pharm and 4 Ph.D students (Pursuing).

 

Somnath De

Somnath De working as Professor and have over 15 years of teaching and research experience. He had more than 20 research and review publications. He is having 10 national as well as international presentations in his credit. He filed one patent. He guided around 24 MPharm and 4 Ph.D students (Pursuing).

 

press releasesRead more...

Roche opens up new possibilities for genomic research in Asia Pacific with next-generation sequencing technology

Roche is advancing its nextgeneration sequencing NGS ambitions in Asia Pacific following the global launch of AXELIOS in June Building on early adoption in South Korea Roche will bring the transformative technology closer to researchers and laboratory leaders across the region through AXELIOS Days

Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses

Charles River Laboratories International Inc announced today that it has entered into definitive agreements to acquire Frontage Holdings Corporations bioanalysis and DMPK operations in Exton Pennsylvania for approximately million in cash subject to customary closing adjustments In addition to the i...

Sino Biological Advances AI-Designed Molecule Validation with 4RISETM

AI can generate protein candidates at an unprecedented speed but experimental validation remains essential to determine whether they properly express bind targets and demonstrate the desired biological properties Sino Biological Inc Shenzhen Stock Exchange SZ a global leader in recombinant protein t...

Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery

Chai Discovery the AI company building a computeraided design suite for proteinbased therapeutics today announced a collaboration with Roche to use Chais AI models and platform in a number of drug discovery programs across its therapeutic areas

PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product

PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia

HUTCHMED China Limited announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia AIHA Sovleplenib is a novel selective oral spleen tyrosine kinase Syk inhibitor

EventsRead more...

09 - 11

Nov 2026

11th Microbiome Movement USA Summit

The Colonnade Hotel, Boston, M...

10 - 11

Nov 2026

Extractables & Leachables Europe

Parkhotel Schӧnbrunn, Vienna,...

11 - 13

Nov 2026

Frontiers in Cancer Science 2026

One Farrer Hotel,1 Farrer Park...

11 - 12

Nov 2026

24 - 25

Nov 2026

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

LATEST NEWSRead more...

IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours

IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...

Bayer’s Asundexian Receives Approval for Secondary Stroke Prevention

Bayer has received approval from the US Food and Drug Administration FDA for asundexian mg tablets marketed under the brand name Sunharbo to reduce the risk of recurrent stroke in adults following a recent noncardioembolic ischaemic stroke or highrisk transient ischaemic attack TIA

Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer

Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC

Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies

Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies

MindWalk Partners with Teva to Support Antibody Discovery Using AI

MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology

CStone Enters into Collaboration with Kimia Therapeutics to Advance Clinical Development of Novel Oncology Drug

CStone Pharmaceuticals has entered into a clinical development collaboration with USbased Kimia Therapeutics to advance a potential firstinclass drug candidate targeting the DNA damage response DDR pathway which plays an important role in the survival of solid tumour cells